SCHEMBL13857747

SCHEMBL13857747

CCN(CC(CO)OC)C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
TTR P02766 1/20 0.33
KIF11 P52732 2/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 2/20 0.32
CHRM2 P08172 2/20 0.32
CHRM1 P11229 2/20 0.32
CHRM3 P20309 2/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10745740 0.74 KCNN4 (0.54) KCNN4CYP2C9TSHRALDH1A1CYP2D6
SCHEMBL20644270 0.72 ALDH1A1 (0.45) KCNN4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL15398955 0.69 KIF11 (0.49) KCNN4KIF11LMNA
SCHEMBL23037535 0.68 CYP2C9 (0.45) KCNN4CYP2C9TSHRALDH1A1CYP2C19
SCHEMBL9693942 0.68 CYP2C9 (0.45) KCNN4CYP2C9TSHRALDH1A1CYP2C19
SCHEMBL15577796 0.65 KCNN4 (0.43) KCNN4ALDH1A1KIF11SIGMAR1
SCHEMBL5704664 0.64 TRPA1 (0.53) CYP2C9TSHRALDH1A1CYP2C19HSD17B10
SCHEMBL1616107 0.64 MEN1 (0.44) KCNN4CYP2C9ALDH1A1CYP2D6CYP2C19
SCHEMBL10335574 0.63 KCNN4 (0.50) KCNN4ALDH1A1CYP2D6KDM4ECHRM3
SCHEMBL2490290 0.63 ALDH1A1 (0.46) KCNN4CYP2C9ALDH1A1CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131624-A1 SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS AVI BIOPHARMA, INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131624-A1 SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS RNMT, O60361, PAM KCNN4 812/4885MAPT 3919/4885CYP2C9 4017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.